LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $127.60 In stock
100 mg $317.50 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M1444

    MDL 29951

    GPR17 agonist, NMDA and fructose 1,6-bisphospha...

    ≥98%
  • C451338

    Clioquinol

    Antifungal agent with neuroprotective activity....

    ≥98%
  • D490280

    DMH-1

    Inhibitor of BMP.

    ≥99%
  • P2000

    PF-03758309 Dihydrochloride

    PAK4 inhibitor.

    ≥99%, ≥99%ee
  • A0922

    Acetyl-L-Carnitine Hydrochloride

    Carnitine derivative, involved in energy homeos...

    ≥98%
  • P200097

    PF-06821497

    EZH2 inhibitor

    ≥99%
  • A5277

    Angiotensin II, human

    Endogenous peptide, involved in vasoconstrictio...

    ≥95%
  • L1784

    Levetiracetam

    SV2A synaptic vesicle inhibitor.

    ≥99%
  • C0365

    Carvedilol

    FIASMA; α1- and β1/2-adrenergic antagonist.

    ≥98%
  • G880000

    GW 405833

    Cannabinoid receptor 2 selective agonist.

    ≥98%
  • L1684

    Levonorgestrel

    Synthetic progestogen; contraceptive.

    ≥98%
  • D1643

    Delta Sleep Inducing Peptide

    Peptide; GABA potentiator, NMDA negative allost...

    ≥95%
  • S5753

    Somatostatin-28 (1-14)

    Endogenous neuropeptide hormone; somatostatin a...

    ≥95%
  • W9600

    WZ-4002

    EGFR (T790M) inhibitor.

    ≥98%
  • M1874

    3-Methyladenine

    Nucleobase (adenine) analog; DNA polymerase inh...

    ≥98%
  • B3374

    Bisacodyl

    Diphenylmethane derivative, stimulates colonic ...

    ≥98%
  • A9715

    AZD-8330

    MEK 1/2 inhibitor.

    ≥98%
  • A7085

    Arvanil

    CB1 agonist, TRPV1 agonist.

    ≥98%
  • S3476

    Sitagliptin Phosphate Monohydrate

    DPP4 inhibitor.

    ≥98%
  • G5320

    GNF-2

    Abl inhibitor.

    ≥98%